Patient description: Patient A is a 30-year-old male who was admitted to the hospital after 10 days of cough, profuse nocturnal sweating and loss of appetite. He had traveled to India 1 months ago and has not any positive history of TB vaccination. He is a previously healthy man, working as an engineer in a high tech company. He doesn't smoke o use any illicit drugs. He was febrile (38 c) with heart rate of 115 b/min, respiratory rate of 22, BP of 125/75 mmHg and O2 sat of 97%. Chest X-ray showed infiltrate in the middle of left lung with diameter of 1.8 cm with signs of cavitation. The sputum smear revealed positive sputum culture for Mycobacterium tuberculosis which are sensitive of the first-line TB drugs (isoniazid, streptomycin, rifampicin and ethambutol). Lab study is reported bellow: Hgb: 13 g/dl WBC: 14000 /mm3 Plt: 300000 /ml AST: 13 U/L ALT: 15 U/L Alk P: 53 U/L Bill total: 0.6 mg/dl Na: 137 mEq/l K: 4 mEq/l Creatinine: 0.5 mg/dl BUN: 10 mg/dl ESR: 120 mm/hr

Clinical trial eligibility criteria: eligible ages (years): 20.0-999.0,  Ankylosing Spondylitis Male or female patients aged ≥ 20 years old Patients meet the Ankylosing Spondylitis of modified New York (1984) for over 3 month duration Patient with active disease at the time of screening as defined by the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score ≧4 and a spinal pain score ≧4 on a Numeric Rating Scale (NSR) Presence of at least one of the following Erythrocyte Sedimentation Rate (ESR) : male≧13 mm/hr ; female≧22 mm/hr C-Reactive Protein (CRP) ≧ 0.5 mg/dl Patients have been treated optimal daily doses of at least two NSAIDs for at least 2 weeks, or documented intolerance to NSAIDs Patient is willing and able to comply with study procedures and sign informed consent Patient may be receiving stable dose of permitted DMARDs (methotrexate at max of 25 mg/week, sulfasalazine at max of 3 g/day) since at least 2 weeks prior screening visit Patient may be receiving stable dose of corticosteroids (eg. Prednisolone ≦10mg/day) since at least 2 weeks prior screening visit  Known hypersensitivity to etanercept or ENIA11 or any of its components Previous unsuccessful treatment with etanercept, anti-TNF monoclonal antibodies or a soluble TNF receptor (e.g., infliximab) Suspected or diagnosed active pulmonary tuberculosis, or other chronic or current infectious disease at discretion of investigator Patients who have a history or evidence of a medical condition that would expose them to an undue risk of a significant adverse event during the course of the trial, including but not limited to hepatic, renal, respiratory, cardiovascular, endocrine, immune, neurological, hematological, gastrointestinal or psychiatric disease as determined by the clinical judgment of the investigator Patients with any of the following laboratory abnormalities: ALT/AST > 3 times ULN, creatinine > 2 mg/dl, WBC < 3,000/mm3, Hemoglobin < 8.5 g/dL, platelet count < 100,000/mm3 (6) Patients have received live attenuated vaccination program within 3 months or BCG vaccine within 12 months prior enrollment Female patient of childbearing potential who is lactating; or has positive urine pregnancy test at Visit 1; or refuse to adopt reliable method of contraception during the study Suspected or diagnosed active for human immunodeficiency, hepatitis B or hepatitis C virus (HCV Ab+ and HCV RNA+)